Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Leftovers, warmed up? Most of PR is old news, rehashed corporate update. More tries to find best K dosing. the phase 2/3 will be sunitinib/K at beth israel, as suggested in update(that is my guess, certainly)

Interesting though is BLURRING 1/2/3- I have not heard this prior.
And what if the 2/3 is anything other than renal ca at beth Israel? i doubt it strongly, but that would be exciting, since it would mean a new target.

RK mentions ovarian, which CEO has hinted about. Anything at all- ovarian, pancreatic- and all those other ugly cancers: would be great to know that CTIX has identified other regimens, partners, trials.

Now all we need is data to show that it works: not in a lab, not on a mouse, not just p21. Of course they are treating people and not biomarkers, and wouldn't some efficacy info be nice. That is still a ways off I believe. Anything at ASCO? One can always hope.

I am afraid, though, that this amounts to old news, rewarmed. Except for 1/2/3 blur